Immunology

Novartis expands immuno-oncology presence

Novartis expands immuno-oncology presence

By

The drugmaker's purchase of private biotech CoStim Pharmaceuticals comes with a host of experimental immuno-oncology agents.

Merck: 2014 is the year of the rebuild

Merck: 2014 is the year of the rebuild

By

The company expects to return to growth in 2015 as it focuses on immunotherapy collaborations.

Merck, Ablynx ink immunotherapy deal

The two will explore cancer-attacking nanobodies.

Analysts put weight on BMS in oncology

Analysts put weight on BMS in oncology

By

Friday's no-nivolumab news event disappointed some, but analysts generally rooted for BMS, which saw year-end sales fall 7%, because of anticipated immuno-oncology success.

Drugmakers carve out immuno-oncology turf

Drugmakers carve out immuno-oncology turf

By

Merck and Celgene are exploring a combination that could solidify their immuno-oncology footholds.

Takeda may be poised to expand IBS treatment category

By

Phase III results of its Crohn's and ulcerative colitis medication show positive patient response in a category among patients who have exhausted other options.

Email Newsletters